Researchers at University of California San Diego School of Medicine have discovered that an enzyme called MICAL2 promotes tumor growth and spread in pancreatic ductal adenocarcinomas, the most common form of pancreatic cancer.
Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.
